TCO-modified monoclonal antibody

A TCO-modified monoclonal antibody is a monoclonal antibody chemically conjugated with trans-cyclooctene (TCO) groups, typically via amine-reactive chemistry (e.g., NHS–TCO), for the purpose of enabling fast and selective bioorthogonal ligation reactions with tetrazine-containing compounds (via IEDDA cycloaddition)[1][2][3]. This modification is frequently used in pretargeted imaging, diagnostics, or therapeutic delivery, allowing for temporally separated targeting and payload delivery, such as with radiolabeled tetrazines for PET imaging[1][3][6]. TCO modification itself does not define a molecular target, receptor, or enzyme, and thus is not a therapeutic target in the classical sense; rather, it is a chemical alteration intended to confer bioorthogonal reactivity to the antibody scaffold. Common issues include a trade-off between increased TCO density (for reaction efficiency) and preservation of antibody biological function and favorable pharmacokinetics[1][2][3][6]. Use of hydrophilic PEG linkers and careful control of modification levels are common strategies to optimize reactivity while limiting negative effects[1][2][3][4]. Key contextual point: - The identity and therapeutic function of a TCO-modified antibody depend entirely on the underlying monoclonal antibody used (such as anti-CD44v6, anti-TfR, etc.), not on the TCO modification itself[1][3][6]. - If specifics (such as the antibody target) are not provided, "TCO-modified monoclonal antibody" is insufficiently defined to map onto canonical target entries.

Other names

TCO-antibodyTCO-conjugated monoclonal antibodyTCO-mAbTCO-labeled monoclonal antibody